Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.
Beam Therapeutics is a biotechnology company engaged in creating genetic medicines based on its base editing technology. It is pioneering the use of base editing, a potential new class of precision genetic medicines, with a vision of providing life-long cures to patients suffering from serious diseases. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the dna.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 19, 2021 | Post-IPO Equity | $260M | 5 | — | — | Detail |
Feb 11, 2020 | Post-IPO Equity | $207M | — | — | — | Detail |
Feb 5, 2020 | IPO | $178M | — | — | — | Detail |
Mar 6, 2019 | Series B | $135M | 8 | — | — | Detail |
May 14, 2018 | Series A | $87M | 3 | ARCH Venture Partners F-Prime Capital | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Casdin Capital | — | Post-IPO Equity |
Cormorant Asset Management | — | Post-IPO Equity |
Farallon Capital Management | — | Post-IPO Equity |
Perceptive Advisors | — | Post-IPO Equity |
Redmile Group | — | Post-IPO Equity |
Altitude Life Science Ventures | — | Series B |
ARCH Venture Partners | — | Series B |
Eight Roads Ventures | — | Series B |
F-Prime Capital | — | Series B |
GV | — | Series B |
Beam Therapeutics has acquired 1 organizations. Their most recent acquisition was Guide Therapeutics on Feb 23, 2021. They acquired Guide Therapeutics for 0.
Date
Company Name
|
Industry | Acquisition Type | Price | |
---|---|---|---|---|
Feb 23, 2021
Guide Therapeutics
|
Biotechnology | acquisition | — | Detail |